Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Travis R. Sexton; Guoying Zhang; Tracy E. Macaulay; Leigh A. Callahan; Richard Charnigo; Olga A. Vsevolozhskaya; Zhenyu Li; Susan Smyth

doi:10.1016/j.jacbts.2018.05.005

Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Travis R. Sexton, Guoying Zhang, Tracy E. Macaulay, Leigh A. Callahan, Richard Charnigo, Olga A. Vsevolozhskaya, Zhenyu Li, Susan Smyth

Research output: Contribution to journal › Article › peer-review

76 Citations (SciVal)

Abstract

Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y₁₂ receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting

Original language	English
Pages (from-to)	435-449
Number of pages	15
Journal	JACC: Basic to Translational Science
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.jacbts.2018.05.005
State	Published - Aug 2018

Bibliographical note

Funding Information:
This work was supported by an investigator-initiated grant from AstraZeneca as well as an R01 from the National Institutes of Health National Heart, Lung, and Blood Institute HL123927. Drs. Smyth and Charnigo have been principal investigators and coinvestigators on AstraZeneca grants, including the one funding this work. Dr. Smyth has served on advisory boards for AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2018

Keywords

inflammation
leukocytes
platelets
pneumonia
sepsis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2018.05.005

Cite this

@article{7bbb39dcdadf4005b38d76e603721862,

title = "Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia",

abstract = "Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting",

keywords = "inflammation, leukocytes, platelets, pneumonia, sepsis",

author = "Sexton, {Travis R.} and Guoying Zhang and Macaulay, {Tracy E.} and Callahan, {Leigh A.} and Richard Charnigo and Vsevolozhskaya, {Olga A.} and Zhenyu Li and Susan Smyth",

note = "Funding Information: This work was supported by an investigator-initiated grant from AstraZeneca as well as an R01 from the National Institutes of Health National Heart, Lung, and Blood Institute HL123927. Drs. Smyth and Charnigo have been principal investigators and coinvestigators on AstraZeneca grants, including the one funding this work. Dr. Smyth has served on advisory boards for AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = aug,

doi = "10.1016/j.jacbts.2018.05.005",

language = "English",

volume = "3",

pages = "435--449",

number = "4",

}

TY - JOUR

T1 - Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

AU - Sexton, Travis R.

AU - Zhang, Guoying

AU - Macaulay, Tracy E.

AU - Callahan, Leigh A.

AU - Charnigo, Richard

AU - Vsevolozhskaya, Olga A.

AU - Li, Zhenyu

AU - Smyth, Susan

N1 - Funding Information: This work was supported by an investigator-initiated grant from AstraZeneca as well as an R01 from the National Institutes of Health National Heart, Lung, and Blood Institute HL123927. Drs. Smyth and Charnigo have been principal investigators and coinvestigators on AstraZeneca grants, including the one funding this work. Dr. Smyth has served on advisory boards for AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2018

PY - 2018/8

Y1 - 2018/8

N2 - Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting

AB - Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting

KW - inflammation

KW - leukocytes

KW - platelets

KW - pneumonia

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=85053848505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053848505&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2018.05.005

DO - 10.1016/j.jacbts.2018.05.005

M3 - Article

AN - SCOPUS:85053848505

VL - 3

SP - 435

EP - 449

IS - 4

ER -

Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this